

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
12 June 2025 (12.06.2025)



(10) International Publication Number
WO 2025/120113 A1

(51) International Patent Classification:

C07K 16/28 (2006.01) A61K 31/5377 (2006.01)
A61P 35/00 (2006.01) A61K 39/00 (2006.01)

(21) International Application Number:

PCT/EP2024/084988

(22) International Filing Date:

06 December 2024 (06.12.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/607,757 08 December 2023 (08.12.2023) US
63/721,853 18 November 2024 (18.11.2024) US

(71) Applicants: **CELGENE CORPORATION** [US/US];
Route 206 and Province Line Road, Princeton, New Jersey
08543 (US). **PFIZER INC.** [US/US]; 66 Hudson Boule-
vard East, New York, New York 10001-2192 (US).

(71) Applicant (for MG only): **PFIZER HEALTHCARE IRE-
LAND UNLIMITED COMPANY** [IE/IE]; The Water-
marque Building, Ringsend Road, Dublin 4, Dublin, D04
K7N3 (IE).


(72) Inventors: **BLAKE-HASKINS, John Andrew**; c/o Pfizer
Inc., 66 Hudson Boulevard East, New York, New York
10001-2192 (US). **FINN, Gregory Joseph**; c/o Pfizer
Inc., 66 Hudson Boulevard East, New York, New York
10001-2192 (US). **SOLTANTABAR, Pooneh**; c/o Pfizer
Inc., 66 Hudson Boulevard East, New York, New York
10001-2192 (US). **ACOSTA, Jorge Castellano**; c/o Cel-
gene Corporation, Route 206 and Province Line Road,
Princeton, New Jersey 08543 (US). **MUELLER, Patrick**;
c/o Celgene Corporation, Route 206 and Province Line
Road, Princeton, New Jersey 08543 (US).

(74) Agent: **ELEND, Almut**; 406 Cambridge Science Park,
Milton Road, Cambridge CB4 0WW (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,

(54) Title: THERAPY FOR THE TREATMENT OF MULTIPLE MYELOMA

PART 1
Dose Escalation
(BOIN approach to select RP2Ds)



PART 2
Dose Optimization




FIG. 2

(57) Abstract: Provided herein are methods of treating and/or managing multiple myeloma, which comprise administering to a patient 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione ("Compound A"), or an enantiomer or a mixture of enantiomers, a tautomer, an isotopolog, a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, in combination with a bispecific antibody comprising a first binding part binding to B cell maturation antigen (BCMA) and a second binding part binding to cluster of differentiation 3 (CD3).

[Continued on next page]

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE